Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
July 17, 2023
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
June 26, 2023
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 12, 2023
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
June 7, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
June 5, 2023
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
May 30, 2023
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
May 24, 2023
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
May 22, 2023
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
May 19, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
May 18, 2023
‹
1
2
3
4
5
…
11
›
Close Menu
Company
Team
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
